Search Results - "MUSTO, P"

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma by Palumbo, Antonio, Cavallo, Federica, Gay, Francesca, Di Raimondo, Francesco, Ben Yehuda, Dina, Petrucci, Maria Teresa, Pezzatti, Sara, Caravita, Tommaso, Cerrato, Chiara, Ribakovsky, Elena, Genuardi, Mariella, Cafro, Anna, Marcatti, Magda, Catalano, Lucio, Offidani, Massimo, Carella, Angelo Michele, Zamagni, Elena, Patriarca, Francesca, Musto, Pellegrino, Evangelista, Andrea, Ciccone, Giovannino, Omedé, Paola, Crippa, Claudia, Corradini, Paolo, Nagler, Arnon, Boccadoro, Mario, Cavo, Michele

“…In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than…”
Get full text

European Myeloma Network guidelines for the management of multiple myeloma-related complications by Terpos, Evangelos, Kleber, Martina, Engelhardt, Monika, Zweegman, Sonja, Gay, Francesca, Kastritis, Efstathios, van de Donk, Niels W C J, Bruno, Benedetto, Sezer, Orhan, Broijl, Annemiek, Bringhen, Sara, Beksac, Meral, Larocca, Alessandra, Hajek, Roman, Musto, Pellegrino, Johnsen, Hans Erik, Morabito, Fortunato, Ludwig, Heinz, Cavo, Michele, Einsele, Hermann, Sonneveld, Pieter, Dimopoulos, Meletios A, Palumbo, Antonio

“…The European Myeloma Network provides recommendations for the management of the most common complications of multiple myeloma. Whole body low-dose computed…”
Get full text

Epoxy-silica particulate nanocomposites: Chemical interactions, reinforcement and fracture toughness by Ragosta, G., Abbate, M., Musto, P., Scarinzi, G., Mascia, L.

“…Epoxy-silica nanocomposites were produced by dispersing silica-organosol particles in TGDDM/DDS resin mixtures. The resulting materials were investigated in…”
Get full text

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival by Ferrero, S, Ladetto, M, Drandi, D, Cavallo, F, Genuardi, E, Urbano, M, Caltagirone, S, Grasso, M, Rossini, F, Guglielmelli, T, Cangialosi, C, Liberati, A M, Callea, V, Carovita, T, Crippa, C, De Rosa, L, Pisani, F, Falcone, A P, Pregno, P, Oliva, S, Terragna, C, Musto, P, Passera, R, Boccadoro, M, Palumbo, A

“…Polymerase chain reaction (PCR)-based minimal residual disease (MRD) analysis is a useful prognostic tool in multiple myeloma (MM), although its long-term…”
Get full text

Do we need to distinguish exosomes from microvesicles in hematological malignancies? by Caivano, A, Del Vecchio, L, Musto, P

Get full text

18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease by Zamagni, E, Nanni, C, Gay, F, Pezzi, A, Patriarca, F, Bellò, M, Rambaldi, I, Tacchetti, P, Hillengass, J, Gamberi, B, Pantani, L, Magarotto, V, Versari, A, Offidani, M, Zannetti, B, Carobolante, F, Balma, M, Musto, P, Rensi, M, Mancuso, K, Dimitrakopoulou-Strauss, A, Chauviè, S, Rocchi, S, Fard, N, Marzocchi, G, Storto, G, Ghedini, P, Palumbo, A, Fanti, S, Cavo, M

“…Identification of patient sub-groups with smoldering multiple myeloma (SMM) at high risk of progression to active disease (MM) is an important goal. 18F-FDG…”
Get full text

High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling by Romano, A., Parrinello, N. L., Simeon, V., Puglisi, F., La Cava, P., Bellofiore, C., Giallongo, C., Camiolo, G., D’Auria, F., Grieco, V., Larocca, F., Barbato, A., Cambria, D., La Spina, E., Tibullo, D., Palumbo, G. A., Conticello, C., Musto, P., Di Raimondo, F.

“…To understand neutrophil impairment in the progression from MGUS through active MM, we investigated the function of mature, high-density neutrophils (HDNs),…”
Get full text

Second primary malignancies in multiple myeloma: an overview and IMWG consensus by Musto, P., Anderson, K.C., Attal, M., Richardson, P.G., Badros, A., Hou, J., Comenzo, R., Du, J., Durie, B.G.M., San Miguel, J., Einsele, H., Chen, W.M., Garderet, L., Pietrantuono, G., Hillengass, J., Kyle, R.A., Moreau, P., Lahuerta, J.J., Landgren, O., Ludwig, H., Larocca, A., Mahindra, A., Cavo, M., Mazumder, A., McCarthy, P.L., Nouel, A., Rajkumar, S.V., Reiman, A., Riva, E., Sezer, O., Terpos, E., Turesson, I., Usmani, S., Weiss, B.M., Palumbo, A.

“…Therapeutic advancements following the introduction of autologous stem cell transplantation and ‘novel’ agents have significantly improved clinical outcomes…”
Get full text

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi by Arcaini, L., Vallisa, D., Rattotti, S., Ferretti, V.V., Ferreri, A.J.M., Bernuzzi, P., Merli, M., Varettoni, M., Chiappella, A., Ambrosetti, A., Tucci, A., Rusconi, C., Visco, C., Spina, M., Cabras, G., Luminari, S., Tucci, M., Musto, P., Ladetto, M., Merli, F., Stelitano, C., d'Arco, A., Rigacci, L., Levis, A., Rossi, D., Spedini, P., Mancuso, S., Marino, D., Bruno, R., Baldini, L., Pulsoni, A.

“…Tumor regression after antiviral therapy (AT) is in favor of an etiological role of hepatitis C virus (HCV) in non-Hodgkin's B-cell lymphomas (NHL). We carried…”
Get full text

The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi by Luminari, S., Biasoli, I., Arcaini, L., Versari, A., Rusconi, C., Merli, F., Spina, M., Ferreri, A.J.M., Zinzani, P.L., Gallamini, A., Mastronardi, S., Boccomini, C., Gaidano, G., D'Arco, A.M., Di Raimondo, F., Carella, A.M., Santoro, A., Musto, P., Federico, M.

“…The role of [18F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) in follicular lymphoma (FL) staging is not yet determined. The aim of the present…”
Get full text

Properties of poly(urea-formaldheyde) microcapsules containing an epoxy resin by Cosco, S., Ambrogi, V., Musto, P., Carfagna, C.

“…Physical properties of urea‐formaldehyde microcapsules containing an epoxy resin are presented and discussed. Microcapsules were prepared by in situ…”
Get full text

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network by van de Donk, Niels W C J, Palumbo, Antonio, Johnsen, Hans Erik, Engelhardt, Monika, Gay, Francesca, Gregersen, Henrik, Hajek, Roman, Kleber, Martina, Ludwig, Heinz, Morgan, Gareth, Musto, Pellegrino, Plesner, Torben, Sezer, Orhan, Terpos, Evangelos, Waage, Anders, Zweegman, Sonja, Einsele, Hermann, Sonneveld, Pieter, Lokhorst, Henk M

“…Monoclonal gammopathy of undetermined significance is one of the most common pre-malignant disorders. IgG and IgA monoclonal gammopathy of undetermined…”
Get full text

Water sorption thermodynamics in glassy polymers endowed with hydrogen bonding interactions by Scherillo, G., La Manna, P., Musto, P., Mensitieri, G.

“…In this contribution, we review and critically compare the results of the analyses we have previously performed on water sorption thermodynamics in a series of…”
Get full text

First‐line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real‐life study on 547 patients to evaluate the long‐term efficacy and tolerability of different chemoimmunotherapy strategies by Autore, Francesco, Tedeschi, A., Benevolo, G., Mattiello, V., Galli, E., Danesin, N., Rizzi, R., Olivieri, J., Cencini, E., Puccini, B., Ferrarini, I., Marino, D., Bullo, M., Rossini, B., Motta, M., Innocenti, I., Fresa, A., Stirparo, L., Petrilli, D., Pasquale, R., Musto, P., Scapinello, G., Noto, A., Peri, V., Zamprogna, G., Hohaus, S., Frustaci, A. M., Piazza, F., Ferrero, S., Laurenti, L.

Get full text

The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) by Luminari, S., Biasoli, I., Versari, A., Rattotti, S., Bottelli, C., Rusconi, C., Merli, F., Spina, M., Ferreri, A.J.M., Zinzani, P.L., Gallamini, A., Franceschetto, A., Boccomini, C., Franceschetti, S., Salvi, F., Raimondo, F.D., Carella, A.M., Micol, Q., Balzarotti, M., Musto, P., Federico, M.

“…[18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. In a…”
Get full text

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis by Gay, F, Oliva, S, Petrucci, M T, Montefusco, V, Conticello, C, Musto, P, Catalano, L, Evangelista, A, Spada, S, Campbell, P, Ria, R, Salvini, M, Offidani, M, Carella, A M, Omedé, P, Liberati, A M, Troia, R, Cafro, A M, Malfitano, A, Falcone, A P, Caravita, T, Patriarca, F, Nagler, A, Spencer, A, Hajek, R, Palumbo, A, Boccadoro, M

“…In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus…”
Get full text

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma by Palumbo, A., Gay, F., Bringhen, S., Falcone, A., Pescosta, N., Callea, V., Caravita, T., Morabito, F., Magarotto, V., Ruggeri, M., Avonto, I., Musto, P., Cascavilla, N., Bruno, B., Boccadoro, M.

“…Bortezomib has shown significant activity in myeloma. In this multicenter trial, we assessed for the first time the combination of bortezomib, doxorubicin and…”
Get full text

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma by Bringhen, S, D'Agostino, M, De Paoli, L, Montefusco, V, Liberati, A M, Galieni, P, Grammatico, S, Muccio, V E, Esma, F, De Angelis, C, Musto, P, Ballanti, S, Offidani, M, Petrucci, M T, Gaidano, G, Corradini, P, Palumbo, A, Sonneveld, P, Boccadoro, M

“…This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide–dexamethasone (wKCyd) in newly…”
Get full text

Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by ‘Rete Ematologica Pugliese’ by Mele, G., Cascavilla, N., Di Renzo, N., Guarini, A., Mazza, P., Melillo, L., Pavone, V., Tarantini, G., Curci, P., Falcone, A. P., Germano, C., Mele, A., Palazzo, G., Palumbo, G., Reddiconto, G., Rossini, B., Specchia, G., Musto, P., Pastore, D.

“…We report herein a multicentre retrospective analysis of 192 consecutive patients with symptomatic refractory/relapsed multiple myeloma (RRMM) treated with…”
Get full text

Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy by Maurillo, L., Spagnoli, A., Candoni, A., Papayannidis, C., Borlenghi, E., Lazzarotto, D., Fianchi, L., Sciumè, M., Zannier, M.E., Buccisano, F., Del Principe, M.I., Mancini, V., Breccia, M., Fanin, R., Todisco, E., Lunghi, M., Palmieri, R., Fracchiolla, N., Musto, P., Rossi, G., Venditti, A.

“…We compared the efficacy of azacitidine (AZA) and decitabine (DEC) in elderly patients with untreated AML, diagnosed according to WHO criteria. In the two…”
Get full text